234 related articles for article (PubMed ID: 18455524)
1. The economic burden of noncervical human papillomavirus disease in the United States.
Hu D; Goldie S
Am J Obstet Gynecol; 2008 May; 198(5):500.e1-7. PubMed ID: 18455524
[TBL] [Abstract][Full Text] [Related]
2. Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea.
Choi I; Lee D; Son KB; Bae S
BMC Public Health; 2020 Jun; 20(1):1035. PubMed ID: 32600300
[TBL] [Abstract][Full Text] [Related]
3. Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
Singini MG; Muchengeti M; Sitas F; Chen WC; Combes JD; Waterboer T; Clifford GM
Int J Cancer; 2024 Jul; 155(2):251-260. PubMed ID: 38577820
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
[TBL] [Abstract][Full Text] [Related]
5. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
Jemal A; Simard EP; Dorell C; Noone AM; Markowitz LE; Kohler B; Eheman C; Saraiya M; Bandi P; Saslow D; Cronin KA; Watson M; Schiffman M; Henley SJ; Schymura MJ; Anderson RN; Yankey D; Edwards BK
J Natl Cancer Inst; 2013 Feb; 105(3):175-201. PubMed ID: 23297039
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review.
Préaud E; Largeron N
J Med Econ; 2013; 16(6):763-76. PubMed ID: 23565814
[TBL] [Abstract][Full Text] [Related]
7. StatBite: Proportion of specific cancers caused by HPV.
J Natl Cancer Inst; 2010 Jun; 102(12):839. PubMed ID: 20530763
[No Abstract] [Full Text] [Related]
8. Human Papillomavirus-Attributable Cancers - United States, 2012-2016.
Senkomago V; Henley SJ; Thomas CC; Mix JM; Markowitz LE; Saraiya M
MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(33):724-728. PubMed ID: 31437140
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of human papillomavirus-related diseases in Italy.
Baio G; Capone A; Marcellusi A; Mennini FS; Favato G
PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
11. Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003.
Ekwueme DU; Chesson HW; Zhang KB; Balamurugan A
Cancer; 2008 Nov; 113(10 Suppl):2936-45. PubMed ID: 18980277
[TBL] [Abstract][Full Text] [Related]
12. Beyond cervical cancer: burden of other HPV-related cancers among men and women.
Chaturvedi AK
J Adolesc Health; 2010 Apr; 46(4 Suppl):S20-6. PubMed ID: 20307840
[TBL] [Abstract][Full Text] [Related]
13. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP; Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
[TBL] [Abstract][Full Text] [Related]
14. Risk of human papillomavirus-associated cancers among persons with AIDS.
Chaturvedi AK; Madeleine MM; Biggar RJ; Engels EA
J Natl Cancer Inst; 2009 Aug; 101(16):1120-30. PubMed ID: 19648510
[TBL] [Abstract][Full Text] [Related]
15. Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region.
Parkin DM; Louie KS; Clifford G
Vaccine; 2008 Aug; 26 Suppl 12():M1-16. PubMed ID: 18945410
[TBL] [Abstract][Full Text] [Related]
16. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE
Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718
[TBL] [Abstract][Full Text] [Related]
17. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark.
Olsen J; Jørgensen TR; Kofoed K; Larsen HK
BMC Public Health; 2012 Dec; 12():1082. PubMed ID: 23244352
[TBL] [Abstract][Full Text] [Related]
18. Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in sub-Saharan Africa: systematic scoping review.
Lekoane KMB; Kuupiel D; Mashamba-Thompson TP; Ginindza TG
BMC Cancer; 2019 Jun; 19(1):563. PubMed ID: 31185951
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ
Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241
[TBL] [Abstract][Full Text] [Related]
20. Health and economic implications of HPV vaccination in the United States.
Kim JJ; Goldie SJ
N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
